Arca
Skip to content
Tools
Tools

NA: Neuraminidase

Protein in Influenza A virus (A/Puerto Rico/8/1934(H1N1)) that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 3
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on NA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved3

  • Oseltamivir
  • Zanamivir
  • Peramivir anhydrous

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Neuraminidase inhibitor.
        OseltamivirApprovedRocheSmall moleculeInhibitor15
        ZanamivirApprovedGSKSmall moleculeInhibitor3
        Peramivir anhydrousApproved—Small moleculeInhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
        Post-exposure Influenza Prophylaxis in a Hospital SettingOseltamivirPhase 3Active, not recruitingUniversity Medical Centre LjubljanaMar 27, 2026
        Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPDOseltamivir—Not yet recruitingTianjin Medical UniversityFeb 6, 2026
        Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With InfluenzaOseltamivirPhase 3RecruitingJoincare Pharmaceutical Group Industry Co., LtdJan 21, 2026
        Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based SettingOseltamivirPhase 3RecruitingCapital Medical UniversityNov 19, 2025
        A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for SuspensionOseltamivirPhase 3Not yet recruitingJiangxi Kvvit Pharmaceutical Co., Ltd.Aug 8, 2025
        Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based SettingOseltamivirNot applicableNot yet recruitingCapital Medical UniversityJan 7, 2025
        A/Texas Flu ChallengeOseltamivir, ZanamivirPhase 1RecruitingEmory UniversityDec 31, 2024
        A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by VirusesOseltamivirPhase 1RecruitingRuijin HospitalNov 18, 2024
        A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaZanamivirPhase 2RecruitingUniversity of OxfordDec 13, 2022
        Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)ZanamivirPhase 2RecruitingGeorge Washington UniversityOct 22, 2020

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2051, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.